In December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) appeared and spread worldwide, triggering a pandemic of respiratory illness. So, there was an urgent need for vaccines ...worldwide. The mRNA-based vaccines are undergoing an accelerated phase of development during this pandemic. WHO has issued interim guidelines for administering the Moderna mRNA-1273 vaccine against COVID-19 based on advice given by the Strategic Advisory Group of Experts on Immunization (SAGE). The significant future directions for study would be comparing and elucidating the immune processes triggered by mRNA vaccine platforms, developing existing methods focused on these mechanisms, and introducing new clinical trials of these vaccines against additional disease targets.
This study aims to reveal the important role and contribution of the Moderna mRNA-1273 vaccine to COVID-19 vaccinology.
Moderna mRNA-1273 vaccine could be the keystone of modern vaccinology in the context of the COVID-19 pandemic.
: The Novel Corona Virus pandemic caused significant morbidity and mortality worldwide. The biochemical parameters in affected individuals can differentiate between moderate and severe COVID-19 ...infection. Early identification will facilitate appropriate care and reduce the mortality.
: In the present study, we are exploring the possibility of association of the data of biochemical investigations done at the time of admission with COVID-19 severity in patients, as timely modulation in medical management could reduce the mortality and shorten hospital stay.
: A cross sectional study including 452RT-PCR positive, moderate to severe cases of COVID-19 patients admitted to a tertiary care centre, New Delhi were enrolled in the study, in the months of June to October 2020.Biochemical profile of moderate and severe COVID 19 patients was evaluated on admission and correlated with severity of the disease.
Out of 452 patients, 331 patients had moderate disease while 121 had severe disease. Total bilirubin in moderate disease was 0.6mg/dl(0.4-0.9) and 0.6mg/dl(0.4-0.8) in severe disease (p=0.780). AST was 46U/L(31-73.75) and 45 U/L(30-76) in moderate and severe disease respectively (p=0.544), while ALT was 42U/L(25-78.25) and 42U/L(26-72)(p=0.936) respectively in moderate and severe disease. The ALP was 111U/L(86.5-165.5) and 106U/L(77-157) in moderate and severe disease respectively (p=0.828). The serum urea in moderate COVID-19 patients was 32mg/dl(22-61) while 42mg/dl(22-94) in severe disease (p=0.016). The serum creatinine in moderate disease was 0.7mg/dl(0.6-1.1) while 0.8mg/dl(0.6-1.8)(p=0.143) in severe disease. The median (IQR) serum HsCRP in moderate disease was 103.2mg/L(9.7-202) and in severe disease it was 103.76mg/L(19.53-181.26)(p=0.132). The median (IQR) LDH level in moderate COVID-19 patients was 245U/L(137.25-372.25) while in severe disease it was 385U/L(278-598)(p<0.001).
: The serum biomarkers Urea and inflammatory marker LDH could serve as potential biomarkers to differentiate between moderate and severe COVID-19 patients.
